Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Boehringer Ingelheim Pharma GmbH
Current Parent Company: Boehringer Ingelheim
Penalty: $73,000,000
Year: 2017
Date: December 19, 2017
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: Teva Pharmaceuticals and Boehringer Ingelheim together agreed to pay $146 million to direct purchasers to settle litigation alleging they conspired to block a generic alternative to the stroke medication Aggrenox. The court documents did not specify how much each company would pay. Here we assume the split the amount equally.
Level of Government: federal
Action Type: private litigation
Court: District of Connecticut
Civil or Criminal Case: civil
Case ID: 3:14md2516
Case Name: In Re: Aggrenox Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: Germany
Ownership Structure of Current Parent: privately held
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.